Matthew Wheater

1.6k total citations
42 papers, 906 citations indexed

About

Matthew Wheater is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Matthew Wheater has authored 42 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Surgery, 17 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Matthew Wheater's work include Testicular diseases and treatments (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Ocular Oncology and Treatments (8 papers). Matthew Wheater is often cited by papers focused on Testicular diseases and treatments (11 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Ocular Oncology and Treatments (8 papers). Matthew Wheater collaborates with scholars based in United Kingdom, United States and Italy. Matthew Wheater's co-authors include Christian H. Ottensmeier, T. Geldart, Edurne Arriola, Simon J. Crabb, Jeremy P. Blaydes, Peter Johnson, Ioannis Karydis, Graham M. Mead, Pui Ying Chan and Peter W. Szlosarek and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Matthew Wheater

41 papers receiving 890 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Wheater United Kingdom	16	430	258	189	187	151	42	906
Ernesto Rossi Italy	19	446 1.0×	250 1.0×	206 1.1×	142 0.8×	76 0.5×	72	894
William Townsend United Kingdom	22	877 2.0×	194 0.8×	107 0.6×	34 0.2×	102 0.7×	68	1.8k
José C. Villasboas United States	18	722 1.7×	172 0.7×	79 0.4×	82 0.4×	44 0.3×	127	1.3k
Rosa M. Dávila United States	19	255 0.6×	144 0.6×	254 1.3×	296 1.6×	193 1.3×	43	1.0k
Shenghua Mao United States	15	191 0.4×	149 0.6×	190 1.0×	57 0.3×	158 1.0×	38	790
Stefania Dell’Oro Italy	15	520 1.2×	110 0.4×	155 0.8×	89 0.5×	83 0.5×	22	1.3k
Konstantinos Linos United States	18	487 1.1×	245 0.9×	490 2.6×	120 0.6×	135 0.9×	147	1.2k
J. Beck Germany	11	161 0.4×	182 0.7×	303 1.6×	99 0.5×	47 0.3×	18	691
L. Laterveer Netherlands	15	316 0.7×	244 0.9×	98 0.5×	77 0.4×	116 0.8×	19	1.3k
Carlos Grande Spain	18	622 1.4×	153 0.6×	160 0.8×	78 0.4×	96 0.6×	82	1.4k

Countries citing papers authored by Matthew Wheater

Since Specialization

Citations

This map shows the geographic impact of Matthew Wheater's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Wheater with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Wheater more than expected).

Fields of papers citing papers by Matthew Wheater

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Wheater. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Wheater. The network helps show where Matthew Wheater may publish in the future.

Co-authorship network of co-authors of Matthew Wheater

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Wheater. A scholar is included among the top collaborators of Matthew Wheater based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Wheater. Matthew Wheater is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dayimu, Alimu, Satish Kumar, David Burke, et al.. (2023). Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma. European Journal of Cancer. 194. 113344–113344. 1 indexed citations

Vigneswaran, Ganesh, Weeratunge Malalasekera, Victoria L. Smith, et al.. (2023). Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma. Melanoma Research. 34(2). 193–197. 2 indexed citations

Karydis, Ioannis, Matthew Wheater, Sachin Modi, et al.. (2022). Liver resection for metastatic uveal melanoma: experience from a supra-regional centre and review of literature. Melanoma Research. 33(1). 71–79. 5 indexed citations

Corrie, Pippa, Sarah J. Welsh, Grant D. Stewart, et al.. (2021). Identification of a microbiome signature predicting immune checkpoint inhibitor outcomes across multiple cancer types in the MITRE study.. Journal of Clinical Oncology. 39(15_suppl). TPS2665–TPS2665. 1 indexed citations

Subramaniam, Shalini, Guy C. Toner, Martin R. Stockler, et al.. (2021). P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).. Journal of Clinical Oncology. 39(6_suppl). TPS390–TPS390. 1 indexed citations

Cullen, Michael, Robert Huddart, Johnathan Joffe, et al.. (2020). The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis. European Urology. 77(3). 344–351. 28 indexed citations

Fischer, Stefanie, Torgrim Tandstad, Gabriella Cohn‐Cedermark, et al.. (2019). Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma.. Journal of Clinical Oncology. 37(7_suppl). 510–510. 1 indexed citations

Schadendorf, Dirk, Lisa Zimmer, Sarah Danson, et al.. (2018). Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Annals of Oncology. 30(2). 317–324. 15 indexed citations

McKenzie, Hayley, Graham M. Mead, Robert Huddart, et al.. (2018). Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer. Clinical Genitourinary Cancer. 16(6). 458–465.e2. 2 indexed citations

10.

Karydis, Ioannis, Alexandra Gangi, Matthew Wheater, et al.. (2017). Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. Journal of Surgical Oncology. 117(6). 1170–1178. 61 indexed citations

11.

Arriola, Edurne, et al.. (2016). Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. OncoImmunology. 5(9). e1209615–e1209615. 15 indexed citations

12.

Arriola, Edurne, Matthew Wheater, Ian Galea, et al.. (2016). Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. Journal of Thoracic Oncology. 11(9). 1511–1521. 97 indexed citations

13.

Karydis, Ioannis, Pui Ying Chan, Matthew Wheater, et al.. (2016). Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. OncoImmunology. 5(5). e1143997–e1143997. 64 indexed citations

14.

Cathomas, Richard, Matthew Wheater, Dirk Klingbiel, et al.. (2015). Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience. Annals of Oncology. 26(9). 1865–1870. 26 indexed citations

15.

Wheater, Matthew, et al.. (2015). Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients. European Journal of Cancer Care. 24(2). 155–162. 21 indexed citations

16.

Powles, Thomas, Matthew Wheater, Omar Din, et al.. (2015). A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. European Urology. 69(3). 450–456. 83 indexed citations

17.

Douglas, James J., Adam Sharp, Julia E. Head, et al.. (2014). Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract. British Journal of Cancer. 110(7). 1759–1766. 23 indexed citations

18.

Cathomas, Richard, Dirk Klingbiel, T. Geldart, et al.. (2014). Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort. Annals of Oncology. 25(8). 1591–1597. 24 indexed citations

19.

Wheater, Matthew, et al.. (2011). The clinical features and management of testicular germ cell tumours in patients aged 60 years and older. British Journal of Urology. 108(11). 1794–1799. 11 indexed citations

20.

Nolan, Luke, et al.. (2010). Late relapse (>2 years) on surveillance in stage I non‐seminomatous germ cell tumours; predominant seminoma only histology. British Journal of Urology. 106(11). 1648–1651. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact